Deqing, China, December 04, 2018 / B3C newswire / -- China-headquartered innovative diagnostic company, Shuwen Biotech, announces today that Dr. Irina Buhimschi will support its strategic plans by acting as an advisor to the company. The seasoned researcher brings over 25 years of experience in maternal fetal medicine, including biomarker discoveries and diagnostic applications.
Dr. Irina Buhimschi is the Director of the Center for Perinatal Research in the Research Institute at Nationwide Children’s Hospital and Professor of Pediatrics and Obstetrics/Gynecology at The Ohio State University in Columbus Ohio. Dr. Buhimschi’s work received numerous awards of excellence at national and international meetings. She has published more than 150 peer-reviewed publications and served on numerous grant review committees for the NIH, March of Dimes and private foundations. She is also the Associate Editor for Pediatric Research and a member of editorial boards for several subspecialty journals.
Dr. Buhimschi’s laboratory previously at Yale University was the first to identify misfolding of proteins and proteostasis derangements in preeclampsia similar to those in Alzheimer’s disease, and has developed the Congo Red test for diagnosis of preeclampsia. Shuwen Biotech has licensed the patented technologies and developed a low cost non-invasive point-of-care detection device for preeclampsia which is expected to be launched in the coming months.
“We are very happy to have Irina joining us, and are eager to draw upon her expertise in maternal fetal medicine for our further development and commercialization of the preeclampsia detection product and other diagnostic products for perinatal conditions.” said Jay Z. Zhang, Shuwen's CEO and Chairman.
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.
Posted by Sabine Duntze, B3C Group GmbH and shared through Newronic®